The Manufacturers Life Insurance Company Sells 291 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

The Manufacturers Life Insurance Company decreased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 3.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,000 shares of the specialty pharmaceutical company’s stock after selling 291 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in ANI Pharmaceuticals were worth $498,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Aquatic Capital Management LLC lifted its position in ANI Pharmaceuticals by 149.6% in the 4th quarter. Aquatic Capital Management LLC now owns 6,740 shares of the specialty pharmaceutical company’s stock worth $373,000 after buying an additional 4,040 shares during the last quarter. Oberweis Asset Management Inc. lifted its position in ANI Pharmaceuticals by 50.8% in the 4th quarter. Oberweis Asset Management Inc. now owns 65,600 shares of the specialty pharmaceutical company’s stock worth $3,626,000 after buying an additional 22,100 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in ANI Pharmaceuticals by 20.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,288 shares of the specialty pharmaceutical company’s stock worth $403,000 after buying an additional 1,220 shares during the last quarter. Stifel Financial Corp lifted its position in ANI Pharmaceuticals by 20.4% in the 4th quarter. Stifel Financial Corp now owns 8,424 shares of the specialty pharmaceutical company’s stock worth $466,000 after buying an additional 1,425 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its position in ANI Pharmaceuticals by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company’s stock valued at $630,000 after purchasing an additional 675 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on ANIP shares. HC Wainwright reiterated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price objective for the company. Truist Financial boosted their price objective on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a research report on Monday, April 21st. Guggenheim reissued a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Finally, StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $80.13.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of the business’s stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $60.07, for a total transaction of $52,921.67. Following the sale, the senior vice president now owns 89,897 shares in the company, valued at approximately $5,400,112.79. The trade was a 0.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Mutz sold 4,000 shares of the business’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total value of $241,800.00. Following the sale, the insider now owns 107,317 shares in the company, valued at approximately $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 7,681 shares of company stock worth $468,698 in the last ninety days. 11.10% of the stock is owned by insiders.

ANI Pharmaceuticals Trading Up 0.8%

Shares of NASDAQ ANIP opened at $59.99 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The business has a fifty day simple moving average of $66.91 and a two-hundred day simple moving average of $60.75. The firm has a market cap of $1.31 billion, a PE ratio of -109.07 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. During the same period in the previous year, the company posted $0.82 EPS. ANI Pharmaceuticals’s revenue was up 43.4% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.